All News

RheumNow Podcast square

Pre-ACR25 (10.24.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and info reports the day before ACR 2025

Read Article
steroid prednisone lab

Can Steroids Be Stopped in Lupus Nephritis?

MedPage Today

Patients with lupus nephritis were more likely to get off chronic corticosteroid treatment, and stay off, when certain factors were in place, researchers said.

Read Article
CNS.demyelinating.jpg

Clinical and Genetic Effects of Neuropsychiatric Lupus

Jack Cush, MD

The clinical features and genetic abnormalities of neuropsychiatric systemic lupus erythematosus shows that NPSLE often means more severe lupus and more organ involvement beyond the central nervous system.

Read Article
autoimmune.disease

SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease

Jack Cush, MD

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have benefits beyond glycemic control, including cardioprotective and nephroprotective effects, with modest weight loss.

Read Article
FDA%20approved2.jpg

FDA Approves Obinutuzumab for Active Lupus Nephritis

Jack Cush, MD

The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis.

Read Article
RheumNow Podcast square

Bad Actor Cofactor (10.17.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more.

Read Article
lupus_0.jpg

Telitacicept Effective in Systemic Lupus Erythematosus

Jack Cush, MD

The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few safety concerns.

Read Article
RheumNow Podcast square

Eating Crow (10.10.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, FDA approvals, and journal articles. In this episode: HMGCR Abs, FDA approvals and Cush eats crow.

Read Article
Telitacicept Effective in Systemic Lupus Erythematosus The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few https://t.co/L0TgynLELD
Dr. John Cush RheumNow ( View Tweet)
FDA has approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. https://t.co/0eGwGnSDYf https://t.co/wnQDVnTEjb

Links:

Dr. John Cush RheumNow ( View Tweet)
Clinical and Genetic Effects of Neuropsychiatric Lupus The clinical features and genetic abnormalities of neuropsychiatric systemic lupus erythematosus shows that NPSLE often means more severe lupus and more organ involvement beyond the central nervous system. https://t.co/7Ujo6Kaf1N
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Obinutuzumab for Active Lupus Nephritis The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis. https://t.co/WbpATY86BY https://t.co/zRONkCUtIx

Links:

Dr. John Cush RheumNow ( View Tweet)
Saphnelo (anifrolumab) has been recommended for approval in EU by CHMP for systemic lupus erythematosus (on top of standard therapy) as a once-weekly pre-filled pen. Recommendation based on TULIP-SC Phase III trial. https://t.co/VRUycfLRtf https://t.co/O7cQfkb8BU

Links:

Dr. John Cush RheumNow ( View Tweet)
Telitacicept Effective in Systemic Lupus Erythematosus The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few https://t.co/lwq8ZUMTQ8
Dr. John Cush RheumNow ( View Tweet)
FDA has approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. https://t.co/0eGwGnSDYf https://t.co/Z6w2iP4u3e

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of biopsy proven lupus nephritis pts (1970-2024) - a total of 324 LN pts followed for median 9.9 yrs -- 30 (9.3%) developed Venous Thromboembolic event (VTE); time from LN to 1st VTE 4.4 yrs. Predictors were SLEDAI-2K score (HR= 1.05) and proteinuria level (HR 1.26)

Dr. John Cush RheumNow ( View Tweet)

Failure of IL-17 inhibition in Lupus nephritis. 31 LN pts enrolled in phase 2 DBRPCT of secukinumab 300 mg IV, but was terminated early for futility (complete renal response at week 52 was lower with secukinumab (24.2%) than with placebo (36.3%). https://t.co/471TolqtFk https://t.co/gKi2Z2MZHS

Links:

Dr. John Cush RheumNow ( View Tweet)

Osteonecrosis: suspect with trauma, high-dose steroids, alcoholism, renal failure, transplantation, SLE, thrombotic states (e.g., sickle cell anemia, hemoglobinopathies), radiation injury, pancreatitis, gout, pregnancy, hyperlipidemia, & caisson disease (decompression sickness) https://t.co/y6iYd5fWZ2

Dr. John Cush RheumNow ( View Tweet)
Multimorbidity in SLE: metanalysis of 3 studies (1175 pts) saw Multimorbidity (by higher Charlson comorbidity index/CCI), is a strong independent predictor of mortality in SLE (OR 3.92). In SLE, the most freq comorbidities were DM, CVD, COPD, renal/lung/CNS Dz https://t.co/fuYUdfC6wE
Dr. John Cush RheumNow ( View Tweet)
Sequencing DNA to find new lupus treatments MUSC geneticist Betty Tsao, Ph.D., will lead a five-year project to identify rare mutations associated with childhood-onset SLE, or lupus, with more than $3.5 million in funding from the National Institute of Arthritis and https://t.co/1vfQ4fK6FX
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×